CD158i (KIR2DS4) Antibody, anti-human, REAfinity™

Name: CD158i (KIR2DS4) Antibody, anti-human, REAfinity™
Availability: InStock

CD158i (KIR2DS4) Antibody, anti-human, REAfinity™Extended ValidationRecombinant

Clone:

REA860

Type of antibody:

Primary antibodies, Recombinant antibodies

Isotype:

recombinant human IgG1

Applications:

FC, MC

Alternative names:

KIR2DS4

Flow cytometry applications forCD158i (KIR2DS4) Antibody, anti-human, REAfinity™

APC
APC-Vio 770
Biotin
FITC
PE
PE-Vio 615
PE-Vio 770
PerCP-Vio 700
Vio Bright B515
VioBlue

Conjugate:

APC

Recommended dilution:

1:50

Remark:

Cells should be stained prior to fixation, if formaldehyde is used as a fixative.

Tested:

QC tested

Products used:

130-114-773, 130-114-616

Protocols:

Cell surface flow cytometry staining protocol (PBS/EDTA/BSA 1:50)

Description:

Human peripheral blood cells (PBMCs) were stained with CD158i (KIR2DS4) antibodies or with the corresponding REA Control (S) antibodies (left image) as well as with CD56 antibodies. Flow cytometry was performed using the MACSQuant^® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Mass cytometry applications forCD158i (KIR2DS4) Antibody, anti-human, REAfinity™

pure

Conjugate:

pure

Products used:

130-122-328

Extended validation for CD158i (KIR2DS4) Antibody, anti-human, REAfinity™

Sensitivity

Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Flow cytometric comparison of different clones for CD158i (KIR2DS4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158i (KIR2DS4) antibodies and with a suitable counterstaining. As a control, CD158i (KIR2DS4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD158i (KIR2DS4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158i (KIR2DS4) antibodies and with a suitable counterstaining. As a control, CD158i (KIR2DS4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD158i (KIR2DS4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158i (KIR2DS4) antibodies and with a suitable counterstaining. As a control, CD158i (KIR2DS4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD158i (KIR2DS4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158i (KIR2DS4) antibodies and with a suitable counterstaining. As a control, CD158i (KIR2DS4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD158i (KIR2DS4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158i (KIR2DS4) antibodies and with a suitable counterstaining. As a control, CD158i (KIR2DS4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation

Post fixation

Comparison of staining pattern on non-fixed and fixed cells using CD158i (KIR2DS4) (REA860). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Comparison of staining pattern on non-fixed and fixed cells using CD158i (KIR2DS4) (REA860). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Comparison of staining pattern on non-fixed and fixed cells using CD158i (KIR2DS4) (REA860). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Comparison of staining pattern on non-fixed and fixed cells using CD158i (KIR2DS4) (REA860). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD158i (KIR2DS4) Antibody, anti-human, REAfinity™

Overview

Clone REA860 recognizes the human CD158i antigen, also known as KIR2DS4, a member of the killer immunoglobulin-like receptor (KIR) family expressed on natural killer (NK) cells and some T cells. CD158i (KIR2DS4) provides an activation signal for NK lytic activity upon interaction with its ligand, HLA-Cw4, in an antigen-independent manner. KIRs are monomeric receptors possessing high allelic polymorphism with either two or three Ig-like extracellular domains. The receptor family can be subdivided functionally according to the length of their cytoplasmic tail in inhibitory and activating KIRs.

Additional information: Clone REA860 displays negligible binding to Fc receptors.

Alternative names

KIR2DS4

Detailed product information

Technical specifications

Clone	REA860
Clonality	monoclonal
Isotype	recombinant human IgG1
Isotype control	REA Control Antibody (S), human IgG1
Host	human cell line
Type of antibody	Primary antibodies, Recombinant antibodies
Species	human
Antigen	CD158i (KIR2DS4)
Alternative names of antigen	KIR2DS4
Molecular mass of antigen [kDa]	31
Distribution of antigen	NK cells, T cells
Entrez Gene ID	3809
RRID	AB_2655362, AB_2655363, AB_2655364, AB_2655365, AB_2655366, AB_2655367, AB_2655368, AB_2655369, AB_2655370, AB_2655371, AB_2655372, AB_2655373, AB_2655374, AB_2655375, AB_2655376, AB_2801684, AB_2801683, AB_2655377, AB_2655378, AB_2801907, AB_2655361

Resources for CD158i (KIR2DS4) Antibody, anti-human, REAfinity™

Documents and Protocols

App notes/customer reports

Cross-reactivity of KIR antibodies

Certificates

Please follow this

link

to search for Certificates of Analysis (CoA) by lot number.

References for CD158i (KIR2DS4) Antibody, anti-human, REAfinity™

Publications

Selvakumar, A. et al. (1997) Polymorphism and domain variability of human killer cell inhibitory receptors. Immunol. Rev. 155: 183-196
Kratz, G. et al. (2004) MHC Class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol 173: 1819-1825

Applications

Extended validation